Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy.[1] Sparsentan is an endothelin and angiotensin II receptor antagonist.[1][3] It is taken by mouth.[1]
It was approved for medical use in the United States in February 2023.[1][4][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]
In February 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a conditional marketing authorization for the medicinal product Filspari, intended for the treatment of adults with primary immunoglobulin A nephropathy (IgAN).[2] The applicant for this medicinal product is Vifor France.[2]
Lokasi Pengunjung: 3.15.10.234